1例化疗药导致Ⅳ度骨髓抑制的病例分析及药学监护  

Case Analysis and Pharmaceutical Care for a Patient with Chemotherapy-induced Ⅳ Degree Myelosuppression

作　　者：唐晓霞[1] 戎佩佩[2] 龚虹云[3] 戴志凌[1] 邹顺[1] 

机构地区：[1]昆明医科大学第二附属医院药学部,昆明650101 [2]武汉大学人民医院药学部 [3]武汉大学人民医院肿瘤中心

出　　处：《中国药师》2016年第9期1716-1718,共3页China Pharmacist

摘　　要：目的:探讨临床药师在化疗致Ⅳ骨髓抑制病例中开展临床药学的切入点及药学监护方法。方法:以对1例培美曲塞联合奈达铂用于晚期肺腺癌出现Ⅳ度骨髓抑制的病例分析为切入点,对该例患者化疗方案、骨髓抑制的发生及治疗过程及可开展的药学服务进行分析总结。结果:临床药师利用药学专业知识最终帮助患者安全度过化疗后的骨髓抑制期,增强了药学监护意识,为保障患者用药安全有效等方面发挥了积极作用。结论:临床药师积极参与药学监护,提供药学服务,有利于患者用药安全、有效。Objective： To investigate the breakthrough points and methods of pharmaceutical care performed by clinical pharmacists for chemotherapy-induced Ⅳ degree myelosuppression. Methods： One advanced lung adenocarcinoma patient suffering from Ⅳ degree myolosuppression after being treated with pemetrexed combined with nedaplatin was selected as the example, and the chemotherapy regimen, the cause and treatment of Ⅳ degree myolosuppression and the pharmaceutical service could be carried out were analyzed. Results： With the help of clinical pharmacists, the patient conquered chemotherapy-induced myelosuppression, and clinical pharmacists enhanced the awareness of pharmaceutical care and played a positive role in the safe and effective drug use. Conclusion： The participation of clinical pharmacists in clinical pharmaceutical care through providing pharmaceutical service is beneficial to safer and more effective drug therapy.

关 键 词：化疗药 骨髓抑制 临床药师 病例分析 药学监护 

分 类 号：R97[医药卫生—药品]